SCHEMBL7217406

SCHEMBL7217406

CC=C(c1ccccc1)C1CCc2ccccc2O1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
CYP2D6 P10635 2/20 0.39
OPRK1 P41145 2/20 0.39
AOC2 O75106 5/20 0.38
MAOA P21397 5/20 0.38
MAOB P27338 5/20 0.38
DAO P14920 1/20 0.38
HTR1A P08908 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
CA2 P00918 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7952332 0.82 HSD11B1 (0.43) HSD11B1CYP2D6OPRK1HDAC3HDAC1
SCHEMBL7952329 0.82 HSD11B1 (0.43) HSD11B1CYP2D6OPRK1HDAC3HDAC1
SCHEMBL7217412 0.78 KDM1A (0.46) HSD11B1CYP2D6OPRK1AOC2MAOA
SCHEMBL7217403 0.78 KDM1A (0.46) HSD11B1CYP2D6OPRK1AOC2MAOA
SCHEMBL2286036 0.76 HPGD (0.49) HSD11B1CYP2D6OPRK1HTR1ASIGMAR1
SCHEMBL29388635 0.76 HPGD (0.49) HSD11B1CYP2D6OPRK1HTR1ASIGMAR1
SCHEMBL230023 0.76 HPGD (0.49) HSD11B1CYP2D6OPRK1HTR1ASIGMAR1
SCHEMBL229558 0.76 HPGD (0.49) HSD11B1CYP2D6OPRK1HTR1ASIGMAR1
SCHEMBL27554734 0.76 HPGD (0.49) HSD11B1CYP2D6OPRK1HTR1ASIGMAR1
Methane SCHEMBL28850179 0.74 HPGD (0.48) HSD11B1CYP2D6OPRK1HTR1ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627652-B1 Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid ALLERGAN, INC. 2003-09-30 US disclosed
US-6624188-B1 Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and ALLERGAN, INC. 2003-09-23 US disclosed
US-5455265-A For mammals; skin disorders, cancer, inflammatory disease, cardiovascular diorders, autoimmune diseases and others ALLERGAN, INC. (US) 1995-10-03 US disclosed
US-5324840-A Skin disorders ALLERGAN, INC. (US) 1994-06-28 US disclosed